AI Medical Service Inc. (hereinafter AIM), a Tokyo, Japan-based med-tech company using deep learning technology to develop endoscopic AI, announced that it raised $70 million (8 billion JPY) in Series C financing.
The round was led by SoftBank Vision Fund 2 (SVF2) and joined by existing investors Globis Capital Partners, World Innovation Lab (WiL), and Incubate Fund.
AIM will use the proceeds of the Series C financing round to accelerate the global adoption of endoscopic AI and finance the development of an in-house cloud-based platform.
Company: AI Medical Service Inc.
Round: Series C
Funding Month: April 2022
Lead Investors: SoftBank Vision Fund 2
Additional Investors: Globis Capital Partners, World Innovation Lab (WiL), and Incubate Fund
Company Website: https://www.ai-ms.com/
Software Category: Endoscopic AI
About the Company: AI Medical Service (AIM) is a Tokyo-based med-tech company established with the mission to "Save Lives All Over the World." Japan leads the world in endoscopic diagnosis and treatment, providing firms and researchers with access to large amounts of high-quality data. AIM is the leading player in the field of endoscopic AI, engaging in joint research with more than 100 medical institutions. By bringing endoscopic AI to a real-world clinical setting as soon as possible, AIM aims to reduce the number of missed cancer diagnoses and save lives around the world.